Drug reference

dotinurad

Uricosuric agent, URAT-1 inhibitor · Antihyperuricemic

Uricosuric agent, URAT-1 inhibitorAntihyperuricemic

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

FDA category + note

Mechanism

Dotinurad is a novel inhibitor of renal uric acid reabsorption, structurally derived from benzbromarone. It acts as a potent inhibitor of URAT-1, localized in the brush-border membrane of the renal proximal tubules, inhibiting the transporter from the luminal side.

Indications

Effective reduction in uric acid levels (currently approved in Japan)

Dosing

Adult: Clinical trials demonstrated effective reduction in uric acid levels at doses of 1, 2, and 4 mg/day.

Pharmacokinetics

Onset

Mass balance calculations suggest that more than 90% of an orally administered dose is absorbed. Peak plasma concentration (CPmax) is reached after approximately 3 h.

Protein binding

Highly plasma bound (>99%).

Metabolism

Glucuronidation and sulfation are the major routes of metabolism.

Excretion

Eliminated with a half-life of approximately 10 h (clearance ~1 L/h).